Department of Gynecology and Obstetrics, The First Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning Province, China.
Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, Liaoning Province, China.
J Ovarian Res. 2024 Feb 12;17(1):39. doi: 10.1186/s13048-024-01359-7.
Ovarian clear-cell cancer is a rare subtype of epithelial ovarian cancer with unique clinical and biological features. Despite optimal cytoreductive surgery and platinum-based chemotherapy being the standard of care, most patients experience drug resistance and a poor prognosis. Therefore, novel therapeutic approaches have been developed, including immune checkpoint blockade, angiogenesis-targeted therapy, ARID1A synthetic lethal interactions, targeting hepatocyte nuclear factor 1β, and ferroptosis. Refining predictive biomarkers can lead to more personalized medicine, identifying patients who would benefit from chemotherapy, targeted therapy, or immunotherapy. Collaboration between academic research groups is crucial for developing prognostic outcomes and conducting clinical trials to advance treatment for ovarian clear-cell cancer. Immediate progress is essential, and research efforts should prioritize the development of more effective therapeutic strategies to benefit all patients.
卵巢透明细胞癌是一种罕见的上皮性卵巢癌亚型，具有独特的临床和生物学特征。尽管进行了最佳的细胞减灭术和铂类为基础的化疗，大多数患者仍会出现耐药和预后不良。因此，已经开发了新的治疗方法，包括免疫检查点阻断、血管生成靶向治疗、ARID1A 合成致死相互作用、靶向肝细胞核因子 1β 和铁死亡。完善预测生物标志物可以实现更个性化的医学，确定哪些患者将从化疗、靶向治疗或免疫治疗中获益。学术研究小组之间的合作对于开发预后结果和开展临床试验以推进卵巢透明细胞癌的治疗至关重要。需要立即取得进展，研究工作应优先开发更有效的治疗策略，使所有患者受益。
